| Safety and Activity Study of an Oral Medication to Treat Moderate to Severe Crohn's Disease (NCT00102921) | Amgen | 2004-08-01 |
| A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease (NCT00265122) | Centocor, Inc. | 2004-04-01 |
| Extracorporeal Photopheresis to Maintain Symptoms Remission During Steroid Withdrawal in Patients With Steroid-Dependent Crohn's Disease (NCT00056355) | National Institute of Allergy and Infectious Diseases (NIAID) | 2003-03-01 |
| Open-label Trial of Leukine in Active Crohn's Disease (NCT00206700) | Genzyme, a Sanofi Company | 2003-02-01 |
| A Study of the Safety and Efficacy of Infliximab (Remicade) in Pediatric Patients With Crohn's Disease (NCT00207675) | Centocor, Inc. | 2003-02-01 |
| Comparison Azathioprine to Mesalazine for the Prevention of Postoperative Recurrence in the Crohn Disease (NCT00976690) | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | 2002-10-01 |
| CNI-1493 for Treatment of Moderate to Severe Crohn's Disease (NCT00038766) | Ferring Pharmaceuticals | 2002-06-01 |
| Study Evaluating rhIL-11 in Active Crohn's Disease (NCT00040521) | Wyeth is now a wholly owned subsidiary of Pfizer | 2002-04-01 |
| Manitoba Inflammatory Bowel Disease Cohort Study (NCT03262649) | University of Manitoba | 2002-03-01 |
| A Long-term Safety Study of Infliximab (Remicade) (NCT00261976) | Centocor, Inc. | 2002-02-01 |
| A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Moderate to Severe Active Crohn's Disease (NCT00207662) | Centocor, Inc. | 2000-07-01 |
| A Study of the Safety and Efficacy of Infliximab (Remicade) in Subjects With Fistulizing Crohn's Disease (NCT00207766) | Centocor, Inc. | 2000-06-01 |
| An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Fistulizing Crohn's Disease (NCT00269841) | Centocor, Inc. | 1996-05-01 |
| An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Crohn's Disease (NCT00269854) | Centocor, Inc. | 1995-06-01 |
| Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity (NCT03941184) | Mayo Clinic | 1995-01-01 |
| The French E3N Prospective Cohort Study (NCT03285230) | Institut National de la Santé Et de la Recherche Médicale, France | 1990-06-15 |
| An Early Access Program For Ustekinumab In Participants With Moderately To Severely Active Crohn's Disease (NCT03362736) | Janssen Research & Development, LLC | |
| Topical Tacrolimus 0.1% Ointment For Treatment Of Cutaneous Crohn's Disease (NCT01233570) | University of Aberdeen | |
| Expanded Access to Upadacitinib (NCT04159597) | AbbVie | |